Symptoms and Survivorship
SYMPTOMS AND SURVIVORSHIP 12000 Oral Abstract Session, Fri, 8:00 AM-11:00 AM Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML). Areej El-Jawahri, Thomas William LeBlanc, Alison Kavanaugh, Jason Webb, Vicki A. Jackson, Toby Christopher Campbell, Nina O’Connor, Selina M. Luger, Ellin Gafford, Jillian Gustin, Bhavana Bhatnagar, Amir Tahmasb Fathi, Gabriela Hobbs, Julia Foster, Showly Nicholson, Debra M. Davis, Hilena Addis, Dagny Vaughn, Nora K. Horick, Jennifer Temel; Massachusetts General Hospital, Boston, MA; Duke University Medical Center, Durham, NC; Duke University, Durham, NC; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Pennsylvania, Philadelphia, PA; Ohio State University, Columbus, OH; The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, OH; Massachu- setts General Hospital, Harvard Medical School, Boston, MA; Duke Cancer Institute, Durham, NC; Massachusetts General Hospital Biostatistics Center, Boston, MA Background: Patients with AML receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during their hospitalization for induction chemotherapy and often receive aggressive care at the end of life (EOL). We sought to examine the effect of integrated palliative and oncology care on QOL, mood, post-traumatic stress (PTSD) symptoms, and EOL outcomes in patients with AML. Methods: We conducted a multi-site randomized trial of integrated palliative and oncology care (n = 86) versus usual oncology care (n = 74) for patients with AML undergoing intensive chemotherapy. Patients assigned to the intervention were seen by palliative care clinicians at least twice per week during their hospitalization for induction chemotherapy and all subsequent hospital- izations.
[Show full text]